Abstract
Purpose
Although hormones play fundamental roles in prostate growth, their clinical significance is not completely clear. Aims of present study were to assess whether testosterone and serum sex hormone levels are predictors of benign prostatic hyperplasia (BPH) or prostate cancer (PC) and to verify whether prostate cancer is associated with low testosterone levels, and to test association between testosterone levels and known prognostic factors in prostate cancer.
Methods
In 206 consecutive patients with benign prostatic hyperplasia or prostate cancer testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin levels were tested and correlated with disease. In patients with prostate cancer, hormone levels were also correlated with known prognostic factors. Predictive value was assessed for age, prostate-specific antigen (PSA), PSA ratio, PSA density, prostate volume and serum sex hormone levels using multiple logistic regression analysis and receiver operating characteristic curves.
Results
Considering sex hormones, only testosterone levels were significantly lower in patients with prostate cancer than those with BPH; testosterone levels appear to be independent predictor of prostate cancer, enhancing predictive accuracy for BPH and PC. Testosterone levels do not seem to be associated with known clinical prognostic factors.
Conclusions
This study supports experimental findings that testosterone levels are predictor of prostate cancer and that prostate cancer is frequently associated with low testosterone levels. In the diagnostic work-up for prostate cancer, adding testosterone determination to PSA test may improve predictive accuracy.
Similar content being viewed by others
References
Vergho DC, Heine K, Wolff JM (2005) The role of PSA in diagnosis of prostate cancer and its recurrence. Pathologe 26:473–478
Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58:475–481
Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10:3943–3953
Singh AS, Chau CH, Price DK, Figg WD (2005) Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol 2:101–107
Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, Almenar S, Llombart-Bosch A (2005) Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 48:745–751
English HF, Kloszewski ED, Valentine E, Santen RJ (1986) Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion, repletion. Cancer Res 46:839
Porter A, Ben-Josef E, Crawford ED, Garde S, Huhtaniemi I, Pontes JE (2001) Advancing perspectives on prostate cancer: multihormonal influences in pathogenesis. Mol Urol 5:181–188
Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H (2000) Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol 38:243–249
Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA, Goffin V (2010) Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 107:15199–15204
Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183
Morgentaler A (2007) Testosterone replacement therapy and prostate cancer. Urol Clin North Am 34:555–563
Morgentaler A, Traish AM (2009) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55:310–320
Morgentaler A, Rhoden EL (2006) Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology 68:1263–1267
Rannikko S, Adlercreutz H (1983) Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4:223–229
Kumar VL, Wadhwa SN, Kumar V, Farooq A (1990) Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 44:122–128
Schatzl G, Brossner C, Schimd S, Kugler W, Roehrich M, Treu T (2000) Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 55:397–402
Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M (2008) Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 80:134–140
Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI (1998) Influence of radical prostatectomy on serum hormone levels. J Urol 160:449
Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V (2007) Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72:375–380
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847–853
Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA (2005) Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173:1935–1937
Zagars GK, Pollack A, von Eschenbach AC (1997) Serum testosterone—a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327
Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F (2011) Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer. doi:10.1002/cncr.26136
Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F (2011) Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 1117:3953–3962
Harper ME, Wilson DW, Jensen HM, Pierrepoint CG, Griffiths K (1987) Steroid hormone concentrations in relation to patient prognosis and prostate tumor grade. J Urol 27:521–524
Chen SS, Chen KK, Lin ATL, Chang H, Wu HH, Chang LS (2002) The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 89:710–713
Porter AT, F.A.C.R.O, Ben-Josef E (2001) Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 6:131–138
Tian W, Osawa M, Horiuchi H, Tomita Y (2004) Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci 95:491–495
Garcia-Cruz E, Huguet J, Piqueras M, Perez Marquez M, Peri L, Izquierdo L, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A (2011) Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy. World J Urol. doi:10.1007/s00345-011-0741-9
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mearini, L., Zucchi, A., Nunzi, E. et al. Low serum testosterone levels are predictive of prostate cancer. World J Urol 31, 247–252 (2013). https://doi.org/10.1007/s00345-011-0793-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-011-0793-x